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Abstract: PURPOSE For optimal management of ductal carcinoma in situ (DCIS), reproducible histopatho-
logical assessment is essential to distinguish low-risk from high-risk DCIS. Therefore, we analyzed in-
terrater reliability of histopathological DCIS features and assessed their associations with subsequent
ipsilateral invasive breast cancer (iIBC) risk. METHODS Using a case-cohort design, reliability was
assessed in a population-based, nationwide cohort of 2767 women with screen-detected DCIS diagnosed
between 1993 and 2004, treated by breast-conserving surgery with/without radiotherapy (BCS ± RT)
using Krippendorff’s alpha (KA) and Gwet’s AC2 (GAC2). Thirty-eight raters scored histopathological
DCIS features including grade (2-tiered and 3-tiered), growth pattern, mitotic activity, periductal fibro-
sis, and lymphocytic infiltrate in 342 women. Using majority opinion-based scores for each feature, their
association with subsequent iIBC risk was assessed using Cox regression. RESULTS Interrater reliability
of grade using various classifications was fair to moderate, and only substantial for grade 1 versus 2 + 3
when using GAC2 (0.78). Reliability for growth pattern (KA 0.44, GAC2 0.78), calcifications (KA 0.49,
GAC2 0.70) and necrosis (KA 0.47, GAC2 0.70) was moderate using KA and substantial using GAC2;
for (type of) periductal fibrosis and lymphocytic infiltrate fair to moderate estimates were found and for
mitotic activity reliability was substantial using GAC2 (0.70). Only in patients treated with BCS-RT,
high mitotic activity was associated with a higher iIBC risk in univariable analysis (Hazard Ratio (HR)
2.53, 95% Confidence Interval (95% CI) 1.05-6.11); grade 3 versus 1 + 2 (HR 2.64, 95% CI 1.35-5.14) and
a cribriform/solid versus flat epithelial atypia/clinging/(micro)papillary growth pattern (HR 3.70, 95%
CI 1.34-10.23) were independently associated with a higher iIBC risk. CONCLUSIONS Using majority
opinion-based scores, DCIS grade, growth pattern, and mitotic activity are associated with iIBC risk in
patients treated with BCS-RT, but interrater variability is substantial. Semi-quantitative grading, in-
corporating and separately evaluating nuclear pleomorphism, growth pattern, and mitotic activity, may
improve the reliability and prognostic value of these features.
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Abstract
Purpose For optimal management of ductal carcinoma in situ (DCIS), reproducible histopathological assessment is essential 
to distinguish low-risk from high-risk DCIS. Therefore, we analyzed interrater reliability of histopathological DCIS features 
and assessed their associations with subsequent ipsilateral invasive breast cancer (iIBC) risk.
Methods Using a case-cohort design, reliability was assessed in a population-based, nationwide cohort of 2767 women with 
screen-detected DCIS diagnosed between 1993 and 2004, treated by breast-conserving surgery with/without radiotherapy 
(BCS ± RT) using Krippendorff’s alpha (KA) and Gwet’s AC2 (GAC2). Thirty-eight raters scored histopathological DCIS 
features including grade (2-tiered and 3-tiered), growth pattern, mitotic activity, periductal fibrosis, and lymphocytic infil-
trate in 342 women. Using majority opinion-based scores for each feature, their association with subsequent iIBC risk was 
assessed using Cox regression.
Results Interrater reliability of grade using various classifications was fair to moderate, and only substantial for grade 1 
versus 2 + 3 when using GAC2 (0.78). Reliability for growth pattern (KA 0.44, GAC2 0.78), calcifications (KA 0.49, GAC2 
0.70) and necrosis (KA 0.47, GAC2 0.70) was moderate using KA and substantial using GAC2; for (type of) periductal 
fibrosis and lymphocytic infiltrate fair to moderate estimates were found and for mitotic activity reliability was substantial 
using GAC2 (0.70). Only in patients treated with BCS-RT, high mitotic activity was associated with a higher iIBC risk in 
univariable analysis (Hazard Ratio (HR) 2.53, 95% Confidence Interval (95% CI) 1.05–6.11); grade 3 versus 1 + 2 (HR 2.64, 
95% CI 1.35–5.14) and a cribriform/solid versus flat epithelial atypia/clinging/(micro)papillary growth pattern (HR 3.70, 
95% CI 1.34–10.23) were independently associated with a higher iIBC risk.
Conclusions Using majority opinion-based scores, DCIS grade, growth pattern, and mitotic activity are associated with 
iIBC risk in patients treated with BCS-RT, but interrater variability is substantial. Semi-quantitative grading, incorporat-
ing and separately evaluating nuclear pleomorphism, growth pattern, and mitotic activity, may improve the reliability and 
prognostic value of these features.
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PALGA  The nationwide network and registry of his-
tology and cytopathology in the Netherlands.
KA  Krippendorff’s alpha
GAC2  Gwet’s AC2
PHA  Proportional hazard assumptions
HR  Hazard Ratio
FEA  Flat epithelial atypia
HER2  Human epidermal growth factor receptor 2
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Background
Ductal carcinoma in situ (DCIS) of the breast is a non-obli-
gate precursor of invasive breast cancer (IBC). Since the 
introduction of organized population-based breast screen-
ing, the incidence of DCIS has increased manyfold [1–3]. 
Although DCIS is almost always treated to avoid progres-
sion to IBC, this has not led to a reduced IBC incidence. 
Breast screening programs are therefore criticized by some 
for being associated with overdiagnosis and overtreatment of 
DCIS [4–6]. It has been reported that a large proportion of 
untreated DCIS will not progress to IBC [7, 8]. Ryser et al. 
reported a 10-year net risk of ipsilateral IBC (iIBC) of 12.2% 
(95% Confidence Interval (95% CI) 8.6–17.1%) for women 
with DCIS grade 1/2 and 17.6% (95% CI 12.1–25.2%) for 
grade 3 [8]. Although based on selected patients, these 
results underline that at least some DCIS lesions have a low 
risk of progression and may thus be overtreated. However, 
reliably distinguishing high- from low-risk DCIS to guide 
treatment is still challenging.
Many studies have tried to find histopathological markers 
that could predict progression of DCIS [9, 10]. So far, no 
single marker ended up being used in clinical practice due to 
lack of conclusive evidence of predictive ability, in part due 
to suboptimal biased study designs in particular due to insuf-
ficient handling of confounders and poorly described study 
groups [10]. Especially grade has been extensively studied 
as a biomarker for the invasive potential of DCIS. The use of 
many different grading systems with partly unclear criteria 
and often only poor to modest interrater reliability makes 
it difficult to evaluate the role of grade in risk stratification 
[11–21].
In addition, various studies have assessed reproducibil-
ity of histopathological evaluation of DCIS lesions. Unfor-
tunately, these studies were frequently based on highly 
selected case sets, assessed by expert breast pathologists 
often after having received instructions or tutorials before-
hand and using reference diagnoses without follow-up data 
[17, 18, 22–28]. The interpretation of results and evalua-
tion of potential bias is further complicated by inadequate 
reporting [29].
This study assesses the interrater reliability of various 
histopathological features in DCIS in a setting which as 
closely as possible reflects daily practice. We subsequently 
evaluate whether these features, based on a more robust 
majority opinion of 38 raters, are associated with risk of 
development of subsequent iIBC.
Methods
Patient selection
We assembled a population-based, nationwide cohort 
of screen-detected primary and pure DCIS, treated with 
breast-conserving surgery with or without adjuvant radio-
therapy (BCS ± RT) between January 1, 1993 and Decem-
ber 31, 2004, by linkage of data from the Netherlands 
Cancer Registry (NCR) with data from the Dutch breast 
cancer screening program [30]. From 1989, the Dutch bien-
nial screening program was gradually introduced, inviting 
women aged 50–69 years and from 1998 aged 50–75 years. 
Screen-detected DCIS was defined as DCIS detected within 
30 months after a first or subsequent positive screening 
examination. The cohort was supplemented with data from 
the nationwide network and registry of histology and cyto-
pathology in the Netherlands (PALGA) [31]. Information 
on age and date at diagnosis, treatment, and if applicable 
subsequent iIBC and vital status was provided by the NCR 
(follow-up data available until January 1, 2011). Patients 
diagnosed with a prior malignancy, other than non-mela-
noma skin cancer, were excluded. The review boards of the 
NCR, PALGA and the Dutch breast cancer screening organi-
zation approved this study.
Interrater reliability analysis
We first assessed the interrater reliability of histopathologi-
cal DCIS features in this cohort using a case-cohort design 
[32]. From the cohort of 2767 women, we randomly sampled 
357 women (subcohort; 13%) and additionally selected all 
177 patients who subsequently developed an iIBC but were 
not included in the random sample for a total of 534 patients. 
Figure 1 shows the selection of patients with exclusions at 
pathology report review (n = 27) and slide review (n = 76). 
Slide review was based on freshly cut slides stained with 
hematoxylin and eosin and in case of uncertainty about the 
in situ nature of the lesion also with cytokeratin 14 by EJG 
(clone LL002; 1/3200 dilution, 32 min at 37 °C + amplifica-
tion, Neomarkers/Thermo Scientific).
For 353 patients the diagnosis of pure DCIS could be 
confirmed and from each lesion a single slide was selected 
with the highest quantity of DCIS. These slides were digi-
tized using an Aperio AT2 scanner (Leica Biosystems) at 
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20 × magnification and uploaded on an online viewing plat-
form (https ://www.slide score .com/). For each DCIS lesion 
a scoring form (see Supplementary methods) was built-in 
with the items: DCIS present (yes or no), grade (1, 2, or 3), 
grade (low or high), growth pattern (flat epithelial atypia 
(FEA), clinging, (micro)papillary, cribriform, or solid) and 
mitotic activity of DCIS (sparse or many mitoses), calcifica-
tions (present or absent), necrosis (present or absent), peri-
ductal fibrosis (absent, subtle, or prominent) and lympho-
cytic infiltrate (absent, subtle, or prominent). For each item, 
a ‘not assessable’ category was also provided. Regarding 
DCIS growth patterns, there is controversy about whether to 
Fig. 1  Flow diagram for 
patient selection and exclusions 
Subcohort randomly selected 
patient group; outside subco-
hort patients who developed 
subsequent ipsilateral invasive 
breast cancer not included in the 
subcohort, iIBC ipsilateral inva-
sive breast cancer; a2 outside 
subcohort patients developed 
invasive breast cancer after a 
mastectomy was performed dur-
ing follow-up, for other reasons 
than iIBC.







No (pure) DCIS   n = 7
Uncertainty on iIBC occurrence   n = 5
Other      n = 4
Excluded aer pathology report review 
n = 16
Paents eligible for study (n = 507)
Material received 
DCIS not confirmed   n = 6
No (pure) DCIS     n = 11
Excluded aer internal slide review 
n = 18
Paents included in reliability study (n = 353)
Final analysis of reliability (n = 342)
      Final analysis of iIBC risk (n = 332)
n = 215                              n = 117
Excluded aer external slide review 
n = 3
Excluded aer external slide reviewa
n = 5
No (pure) DCIS   n = 9
2=nrehtO
Excluded aer pathology report review 
n = 11 
DCIS not confirmed   n = 22
No (pure) DCIS   n = 36
Excluded aer internal slide review 
n = 58 
Excluded aer external slide review 
n = 8
Excluded aer external slide review 
n = 5
 n = 286 (83%)                     n = 143 (89%) 
  n = 220                   n = 122 
  n = 228                   n = 125 
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consider FEA as a subtype of DCIS (clinging, monomorphic 
type) or not; therefore, this option was included as possible 
DCIS growth pattern.
European raters with varying expertise were invited to 
participate in the study. Each rater was assigned a study 
set of 146 cases to score independently, blinded to subject 
information. Raters were not given instructions regarding 
the (interpretation of) histopathological features and were 
requested to score as they would in daily practice to provide 
an unbiased baseline measure of reliability. Further details 
on rater selection, participation, and the scoring process are 
described in Supplementary methods.
Statistical analysis
In total, 11 patients were excluded from reliability analy-
sis because > 50% of raters considered their lesion as no 
DCIS/not assessable (often considering atypical ductal 
hyperplasia/FEA as alternative diagnosis; n = 5) or > 25% 
commented on suboptimal slide quality (n = 6). If DCIS was 
not confirmed, any scores for following histopathological 
features were ignored. Scores for type of fibrosis were only 
considered when periductal fibrosis was present according 
to the majority opinion. Raters were excluded for the analy-
sis of single histopathological features when they scored an 
item as ‘not assessable’ in > 50% of their study set.
Krippendorff’s alpha (KA), Gwet’s AC2 (GAC2), and 
percentage agreement were calculated to assess interrater 
reliability (‘not assessable’ scores were excluded) [33, 34]. 
KA and GAC2 are applicable to studies involving nominal/
ordinal data and multiple raters scoring different subsets. A 
weighted analysis using linear weights was used for ordinal 
variables with > 2 categories. Interpretation was performed 
according to Landis and Koch [35]. Recategorization of 
grade, periductal fibrosis, and lymphocytic infiltrate was 
undertaken during analysis to evaluate reliability using dif-
ferent cut-offs.
For the analysis of subsequent iIBC risk, an additional 
10 patients were excluded, because > 25% of the raters con-
sidered an invasive carcinoma component (mainly micro-
invasion) to be present adjacent to DCIS (n = 8) or because 
the patient underwent a mastectomy before developing iIBC 
(n = 2). For a detailed comparison of clinical characteristics 
between in- versus excluded patients see Supplementary 
Table S1.
Associations of histopathological features, treatment, age 
at diagnosis, and period of diagnosis (1993–1998, reflect-
ing the screening implementation phase, versus 1999–2004, 
reflecting full nationwide coverage) with risk of iIBC was 
assessed using Cox models. Analyses were performed irre-
spective of treatment as well as separately for BCS alone and 
BCS + RT. Interactions with treatment were also considered. 
Proportional hazard assumptions (PHA) were tested using 
residual-based and graphical methods. In case the PHA 
was violated, a time factor was added, and the associations 
were estimated for different time-periods (i.e., for the first 
5 years and after 5 years). For the histopathological fea-
tures the majority opinion, i.e., the most frequently assigned 
category, was used in the analysis (‘not assessable’ scores 
were excluded). In case of equal frequencies, the presence 
of a histopathological feature was chosen over absence, the 
highest grade, the most complex growth pattern (i.e., cribri-
form/solid), many over sparse mitoses, prominent over sub-
tle presence for periductal fibrosis and lymphocytic infiltrate 
and the least common type of fibrosis (i.e., myxoid). Time to 
iIBC was compared between women with low-grade DCIS 
versus high-grade DCIS and women treated with BCS + RT 
versus BCS alone using median test. Clinicopathological 
factors were entered in multivariable models including treat-
ment, based on a P value ≤ 0.15 in univariable analyses. 
Barlow’s inverse probability weights were used to adjust 
the partial likelihood function for case-cohort analysis with 
robust variance estimation [32]. Fit of non-nested models 
was compared using Akaike’s and Bayesian information 
criteria. Two-sided P values ≤ 0.05 were considered statis-
tically significant. All statistical analyses were performed 
using Stata/SE (version 13.1, Statacorp).
Results
Interrater reliability
The mean number of scores per slide was 14 (range 12–15) 
(Supplementary Table S2). The raters consisted of a mixed 
group (Supplementary Table S3), about half of them work-
ing in the Netherlands and half in other European coun-
tries within a wide range of laboratories regarding size and 
degree of specialization. Forty-seven percent of raters were 
members of the European Working Group of Breast Screen-
ing Pathologists. The diagnosis of DCIS was confirmed in 
98.6% of the patients based on the majority opinion.
The interrater reliability for the 3-tiered grading system 
(grade 1, 2, or 3), the most commonly used histopathologi-
cal feature, was only fair (KA 0.34; 95% CI 0.30–0.39) to 
moderate (GAC2 0.52; 95% CI 0.50–0.55; Table 1). Using 
a 2-tiered grading system (either low versus high grade or 
grade 1 + 2 versus grade 3) did not improve reliability. When 
the 3-tiered grading was recategorized into a category for 
grade 1 and a category for grade 2 + 3 combined, the reliabil-
ity was substantial using GAC2 (0.78; 95% CI 0.74–0.82).
Comparable moderate (KA) to substantial (GAC2) reli-
ability was found for growth pattern, necrosis, and calci-
fications, which are all features assessed in daily practice 
within the context of DCIS. FEA was scored 38 times in 24 
different patients (representing 0.76% of all evaluations); in 
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only 1 patient FEA was the majority opinion. Reliability did 
not change when FEA scores were excluded from analysis. A 
striking discrepancy in reliability was found for the assess-
ment of mitotic activity with only fair reliability when con-
sidering KA (0.24) but substantial reliability based on GAC2 
(0.70). In a 3-tiered system (absent, subtle, or prominent 
presence), lymphocytic infiltrate showed moderate reliabil-
ity, which was slightly better than the interrater reliability for 
periductal fibrosis. Recategorization, comparing periductal 
fibrosis presence with absence led to a moderate reliability 
(GAC2 0.53).
Risk of subsequent iIBC after DCIS
Subcohort patients were diagnosed with DCIS at a median 
age of 58.4 (interquartile range 53.4–64.0) and treated by 
BCS alone in 40.5% (87 patients) and by BCS + RT in 59.5% 
(128 patients). After a median follow-up of 11.2 years (inter-
quartile range 8.6–14.1), 20 patients developed an iIBC in 
the subcohort. DCIS was assigned grade 1 in 10.7%, grade 
2 in 53.5%, and grade 3 in 35.8%, based on the majority 
opinion. Median time to iIBC was 5.3 years (interquartile 
range 3.3–7.6 years). Time to subsequent iIBC for women 
with low-grade DCIS did not differ significantly from those 
with high-grade DCIS (median 5.3 years versus 5.6 years, 
respectively, P = 0.57). Time to iIBC for women treated with 
BCS + RT (median 5.9 years) did also not differ significantly 
from those treated with BCS alone (median 5.1 years); 
P = 0.12). Table 2 shows clinicopathological characteristics 
of the subcohort and of all patients who developed an iIBC 
and Fig. 2 depicts photomicrographs of several histopatho-
logical DCIS features based on the majority opinion. 
In univariable analysis, patients treated with BCS alone 
had a much higher risk of iIBC than patients treated with 
BCS + RT with a Hazard Ratio (HR) of 4.80 (95% CI 
2.49–9.24) in the first 5 years and a HR of 2.47 after 5 years 
(95% CI 1.42–4.30; Supplementary Table S4). In patients 
treated with BCS alone, grade 3 (versus grade 1 + 2 com-
bined), a cribriform/solid growth pattern (versus FEA, cling-
ing, and (micro)papillary growth pattern), and mitotically 
active DCIS (versus DCIS with low mitotic activity) were 
also associated with a higher iIBC risk, whereas in patients 
treated with BCS + RT these associations were not found. 
In univariable analysis, a significant interaction with treat-
ment was found for grade 3 versus 1 + 2 (P = 0.028) and for 
growth pattern (P = 0.023).
In multivariable analysis, a model which, besides treat-
ment, included grade 3 versus grade 1 + 2 and growth pattern 
(cribriform and solid versus FEA, clinging, and (micro)pap-
illary) best predicted the risk of developing iIBC in patients 
treated with BCS alone, while grade and growth pattern 
were not associated with iIBC risk in patients treated with 
BCS + RT (Table 3). The risk of developing iIBC did not dif-
fer between patients with DCIS grade 1/2 and FEA, clinging, 
or (micro)papillary growth pattern who were treated with 
BCS alone or BCS + RT. Figure 3 shows cumulative risk of 
iIBC based on categories derived from this model.
Discussion
To the best of our knowledge, this is the first study com-
bining a comprehensive interrater reliability study in 
DCIS, reflecting daily practice as closely as possible, with 
an analysis of iIBC risk based on the majority opinion of 
Table 1  Agreement, Gwet’s AC2 (GAC2), and Krippendorff’s alpha (KA) coefficients per histopathological feature
GAC2 Gwet’s AC2, KA Krippendorff’s alpha, weighted analysis was performed for ordinal features with more than 2 categories using linear 
weights (grade 1–3, periductal fibrosis, and lymphocytic infiltrate), CI confidence interval
Histopathological feature Agreement (%) 95% CI (%) GAC2 95% CI KA 95% CI
Grade (1, 2 or 3) 76.4 75.27–77.52 0.52 0.50–0.55 0.34 0.30–0.39
Grade (1 versus 2 + 3) 83.5 81.33–85.68 0.78 0.74–0.82 0.35 0.28–0.42
Grade (1 + 2 versus 3) 69.3 66.94–71.63 0.43 0.38–0.49 0.34 0.29–0.38
Grade (low versus high) 72.8 70.54–75.12 0.52 0.47–0.57 0.38 0.32–0.44
Dominant growth pattern 84.8 82.58–86.97 0.78 0.75–0.82 0.44 0.37–0.51
Calcifications 81.1 78.81–83.40 0.70 0.65–0.75 0.49 0.43–0.54
Necrosis 81.4 79.12–83.64 0.70 0.66–0.75 0.47 0.41–0.53
Mitotic activity 78.5 76.12–80.97 0.70 0.65–0.74 0.24 0.19–0.29
Periductal fibrosis (absent, subtle or prominent presence) 70.9 69.71–72.13 0.37 0.34–0.39 0.25 0.22–0.29
Periductal fibrosis (present versus absent) 71.2 68.82–73.48 0.53 0.48–0.58 0.23 0.18–0.28
Type of periductal fibrosis (if present) 70.5 67.57–73.37 0.50 0.44–0.57 0.26 0.21–0.31
Lymphocytic infiltrate (absent, subtle or prominent presence) 77.1 75.82–78.36 0.50 0.47–0.53 0.42 0.38–0.47
Lymphocytic infiltrate (present versus absent) 73.0 70.51–75.40 0.51 0.45–0.56 0.38 0.33–0.43
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Table 2  Clinical characteristics 
and histopathological 
characteristics (based on the 
majority opinion) of the study 
population
subcohort randomly selected patient group, iqr interquartile range
* Six out of all patients with iIBC developed breast cancer metastases only
**Sixteen patients from the subcohort developed an iIBC and four developed breast cancer metastases only
a 1993–1998 reflecting part of the screening implementation phase and 1999–2004 reflecting full nation-
wide coverage
b In one patient, growth pattern was scored as not assessable by all raters and was therefore excluded (n 
included patients = 331); FEA = flat epithelial atypia
c For type of fibrosis, patients were only included when according to the majority opinion periductal fibrosis 
was present, either subtle or prominent (n included patients = 268)
Number of DCIS patients (%) All patients with iIBC 137* Subcohort 215**
Treatment
 BCS + RT 42 (30.7) 128 (59.5)
 BCS alone 95 (69.3) 87 (40.5)
Age at DCIS diagnosis, years, median (iqr) 57.5 (53.1–63.6) 58.4 (53.4–64.0)
Age at DCIS diagnosis, years (quartiles)
 ≥ 49.5—≤ 53.4 37 (27.0) 54 (25.1)
 > 53.4—≤ 58.2 36 (26.3) 50 (23.3)
 > 58.2—≤ 63.8 32 (23.4) 56 (26.1)
 > 63.8—≤ 75.6 32 (23.4) 55 (25.6)
Period of DCIS  diagnosisa
 1993—1998 76 (55.5) 82 (38.1)
 1999—2004 61 (44.5) 133 (61.9)
 Median follow-up, years (iqr) 11.2 (8.6–14.1)
 Time to iIBC, years, median (iqr) 5.3 (3.3–7.6)
Grade (1,2 or 3)
 Grade 1 10 (7.3) 23 (10.7)
 Grade 2 67 (48.9) 115 (53.5)
 Grade 3 60 (43.8) 77 (35.8)
Grade (low versus high)
 Low grade 31 (22.6) 60 (27.9)
 High grade 106 (77.4) 155 (72.1)
Dominant growth  patternb
 FEA, clinging, (micro)papillary 14 (10.2) 34 (15.9)
 Cribriform, solid 123 (89.8) 180 (84.1)
Calcifications
 Present 103 (75.2) 168 (78.1)
 Absent 34 (24.8) 47 (21.9)
 Necrosis
 Present 109 (79.6) 167 (77.7)
 Absent 28 (20.4) 48 (22.3)
Mitoses
 Sparse 114 (83.2) 198 (92.1)
 Many 23 (16.8) 17 (7.9)
Periductal fibrosis
 Absent 28 (20.4) 41 (19.1)
 Subtle 73 (53.4) 102 (47.4)
 Prominent 36 (26.3) 72 (33.5)
Type of periductal  fibrosisc
 Sclerotic 80 (73.4) 133 (76.4)
 Myxoid 29 (26.6) 41 (23.6)
Lymphocytic infiltrate
 Absent 38 (27.7) 77 (35.8)
 Subtle 65 (47.5) 89 (41.4)
 Prominent 34 (24.8) 49 (22.8)
765Breast Cancer Research and Treatment (2020) 183:759–770 
1 3
a large group of raters. This approach minimizes the mud-
dling effect of interrater variability and subjectivity on 
the evaluation of the prognostic value of histopathologi-
cal features. It will improve our ability to identify those 
histopathological DCIS features that matter the most in 
terms of iIBC risk, on which future studies which aim to 
optimize reliability should focus.
Fig. 2  Photomicrographs from 
histopathological DCIS features 
based on the majority opinion. 
a low-grade DCIS (hematoxylin 
and eosin (H&E); × 200), b 
high-grade DCIS (H&E; × 200), 
c many mitoses (H&E; × 200), d 
necrosis (H&E; × 200), e subtle 
periductal fibrosis (H&E; × 50), 
f prominent periductal fibrosis 
(H&E; × 50), g sclerotic peri-
ductal fibrosis (H&E; × 50), 
h myxoid periductal fibrosis 
(H&E; × 50), i subtle peri-
ductal lymphocytic infiltrate 
(H&E; × 50), j prominent 
periductal lymphocytic infiltrate 
(H&E; × 50)
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In univariable analysis, patients treated with radiotherapy 
after BCS had a strongly reduced risk of iIBC compared to 
those treated by BCS alone, as was already shown previously 
[30, 36, 37]. Also grade 3 (versus grade 1 + 2 combined), a 
high mitotic activity and a cribriform/solid growth pattern 
(versus FEA, clinging, or (micro)papillary growth pattern) 
were associated with increased iIBC risk in patients treated 
with BCS alone. In multivariable analysis however, only 
grade 3 (versus grade 1 + 2) and a cribriform/solid growth 
pattern were independently associated with an increased 
iIBC risk. Mitotic activity did not add any predictive value 
to grade 3 versus 1 + 2 and growth pattern in a multivari-
able model, though this is likely due to collinearity with 
grade. Another important finding in our study is that no his-
topathological features were associated with iIBC risk in 
the patients treated with BCS + RT. Although women in our 
study were not randomized for treatment arm, this finding 
may suggest that radiotherapy neutralizes the effect of these 
classical histopathological features. This is also in line with 
the fact that within the large randomized controlled trials 
of RT in DCIS no subgroup could be identified without RT 
benefit [36].
So far, grade is the sole histopathological feature in DCIS 
that is used in clinical practice and also has an impact on 
eligibility in the context of clinical trials investigating the 
safety of active surveillance in low-risk DCIS [38–40]. In 
general, only women over the age of 45 or 50 with screen-
detected calcifications associated with DCIS grade 1 or 
grade 2 are eligible in these trials. A three-tiered grading 
system is used for this selection purpose. Our study sup-
ports the rationale to distinguish between grade 1 + 2 versus 
grade 3 as DCIS grade 3 is independently associated with 
an increased risk of iIBC in patients treated with BCS alone. 
Unfortunately, the interrater reliability of assessing grade 
using either a 3-tiered grading system (grade 1, 2, or 3) or 
a 2-tiered system differentiating grade 1 + 2 combined ver-
sus grade 3 was only fair when considering KA and at best 
moderate based on the GAC2.
The interrater reliability for growth pattern was moder-
ate (KA) to substantial (GAC2). The predictive ability of 
Table 3  Associations of histopathological features with subsequent iIBC in multivariable analysis
n total number (number of patients with subsequent iIBC), HR Hazard Ratio, CI confidence interval, P P value, REF reference, FEA flat epithe-
lial atypia
Histopathological feature BCS alone BCS + RT Treatment 
interaction
n HR (95% CI) P n HR (95% CI) P P
Grade (1 + 2 versus 3) 0.017
 1 + 2 107 (52) REF 104 (28) REF
 3 62 (43) 2.64 (1.35–5.14) 0.005 58 (14) 0.79 (0.38–1.62) 0.52
Dominant growth pattern 0.022
 FEA/clinging/(micro)papillary 23 (7) REF 23 (7) REF
 Cribriform/solid 146 (88) 3.70 (1.34–10.23) 0.012 139 (35) 0.77 (0.32–1.85) 0.56
Fig. 3  Kaplan–Meier curve 
illustrating iIBC incidence after 
diagnosis of DCIS treated by 
BCS alone. GP growth pattern, 
other flat epithelial atypia, 
clinging and (micro)papillary 
growth pattern. The red dashed 
reference line depicts the 
maximum reached incidence in 
patients with DCIS grade 3 with 
a cribriform/solid growth pat-
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grade and growth pattern has been intensively studied pre-
viously, with conflicting results [10]. Factors such as sub-
stantial interrater variability, grading system used, bias in 
designs, and relying on histopathological assessments of a 
single pathologist’s opinion may have resulted in these dif-
ferent findings [10]. Interrater reliability based on GAC2 
was higher overall, when histopathological features showed 
strongly skewed distribution and when agreement was 
already very high (i.e., grade 1 versus 2 + 3, growth pattern, 
and mitotic activity). Under these circumstances, a GAC2 
test may result in more accurate reliability coefficients, as 
was previously shown in comparison with Cohen’s kappa, 
which overestimates the concordance attributed due to 
chance alone in these situations leading to lower reliability 
coefficients [41].
In view of the prognostic value and interrater reliability 
observed in our study, it is questionable whether it is safe to 
base clinical treatment decisions solely on the assessment of 
classical histopathological features. Here, we propose four 
strategies that may improve risk stratification in DCIS.
Within the context of DCIS, the three features with rea-
sonable prognostic value (grade 1 + 2 versus 3, growth pat-
tern, and mitotic activity) are currently used in many grad-
ing systems, but without clear definitions and rules about 
how to value each feature. We therefore firstly would sug-
gest to objectify histological grading by using a numerical 
semi-quantitative scoring system which separately evaluates 
each of these features, analogous to the modified Bloom 
and Richardson grading system for IBC [42, 43]. Dichoto-
mous scoring systems may further improve reliability and 
prognostic value and should be further explored evaluating 
different cut-offs [44, 45].
Secondly, performing additional immunohistochem-
istry to assign specific DCIS profiles may add prognostic 
value, possibly only in subsets of patients (i.e., grade 2). 
Previously, associations were reported of human epidermal 
growth factor receptor 2 (HER2)-positive, estrogen recep-
tor (ER)-negative DCIS, and DCIS with high cyclooxyge-
nase 2, p16, and Ki-67 levels with increased iIBC risk [9, 
10, 46, 47]. These markers would be good candidates for 
further exploration. Automated scoring within this context 
may result in more standardized and objective assessment 
[48–51]. Previously, a 3-tiered grading system in DCIS, 
combining nuclear grade according to the Van Nuys criteria 
with automated Ki-67 count, was reported to show excellent 
correlation with immunohistochemical markers of reported 
biological relevance such as ER and HER2 [9, 46, 47, 50].
Thirdly, alternative approaches using pathology informa-
tion such as artificial intelligence-based methods should also 
be considered in search for clinically relevant biomarkers in 
DCIS [52]. Recently, others have developed a whole slide 
image-based machine learning model, which accurately 
predicted the risk of an invasive or in situ recurrence and 
significantly outperformed traditional clinicopathological 
variables [53].
Lastly, besides pathology, other criteria could also be 
incorporated in clinical decision schemes, e.g., as in cur-
rent active surveillance trials requiring DCIS to be screen-
detected based on calcifications only without clinical symp-
toms and diagnosed on representative vacuum-assisted 
biopsies [38–40].
Our study had several limitations. From our study pop-
ulation, each rater scored a different subset of patients. 
Therefore, we were not able to analyze the association of 
histopathological DCIS features with iIBC risk per rater or 
grading system used and to study the effect of interrater vari-
ability on risk stratification. However, the resulting immense 
workload would probably have caused major rater-dropout. 
Also tissue slides were digitally assessed using research 
technology producing images of somewhat lower resolution. 
This may have led to difficulty of assessing histopathological 
features requiring great detail, such as mitotic activity. Our 
reliability study was nonetheless performed under condi-
tions as close as possible to clinical practice, as a large set 
of non-selected DCIS cases from a population-based cohort 
were reviewed by a large group of raters with varying levels 
of expertise without provision of instructions or tutorials 
beforehand. And lastly, data on margin status and DCIS 
lesion size, factors potentially associated with the risk of 
iIBC, were not collected in a standardized way [10, 46, 47, 
54]. However, Dutch guidelines state that a re-excision or 
mastectomy is obligatory in case of involved margins after 
a primary excision. An explorative analysis using the avail-
able data on margin status indeed showed no significant dif-
ference in the risk of iIBC for positive margins and even a 
protective effect for close margins in women treated with 
BCS alone in comparison to women with negative margins, 
suggesting they were subjected to re-excisions.
Conclusions
We evaluated the prognostic value of histopathological 
DCIS features to inform risk stratification using a unique, 
combined approach. Our study showed substantial interrater 
variability in the classification of histopathological DCIS 
features, while using rater majority opinions, minimizing 
the muddling effect of interrater variability, DCIS grade, 
growth pattern, and mitotic activity were associated with 
the risk of subsequent ipsilateral invasive breast cancer after 
DCIS in patients treated with BCS without radiotherapy. A 
semi-quantitative grading system incorporating and sepa-
rately evaluating nuclear pleomorphism, growth pattern, and 
mitotic activity, analogue to IBC grading, may improve the 
reliability and prognostic value of these histopathological 
features.
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